Dupilumab-Associated Blepharoconjunctivitis: Clinical and Morphological Aspects

被引:1
|
作者
Serino, Federica [1 ,2 ]
Dattilo, Valeria [1 ,2 ]
Cennamo, Michela [1 ,2 ]
Roszkowska, Anna Maria [3 ]
Gola, Massimo [4 ]
Magliulo, Manfredi [4 ]
Magnaterra, Elisabetta [4 ]
Mencucci, Rita [1 ,2 ]
机构
[1] Careggi Univ Hosp, Neuromuscular & Sense Organs Dept, Eye Clin, I-50139 Florence, Italy
[2] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, I-50019 Florence, Italy
[3] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, I-98166 Messina, Italy
[4] Azienda USL Toscana Ctr, Allergol & Pediat Dermatol Unit, I-50122 Florence, Italy
关键词
Dupilumab; atopic dermatitis; meibomian glands; cornea; DRY EYE DISEASE; ATOPIC-DERMATITIS;
D O I
10.3390/biomedicines11123104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose: To describe the clinical and morphologic changes in the ocular surface microstructure of patients affected with moderate-to-severe Atopic Dermatitis (AD) before and during Dupilumab treatment. Methods: This is a monocentric observational study on thirty-three patients affected with AD before and during Dupilumab treatment. All patients underwent a slit-lamp examination: complete clinical assessment, Break Up Time test (BUT), Schirmer test, and corneal staining grading (Oxford scale) were performed. Meibomian Glands Dysfunction (MGD) evaluation (Meibography), Non-invasive Keratograph Break Up Time test (NIKBUT), Tear Meniscus Height (TMH), and ocular Redness Score (RS) have been investigated using an OCULUS Keratograph. In vivo images of the conjunctiva, cornea, and meibomian glands have been acquired by confocal microscopy. Results: Sixty-six eyes were included in our study: twenty-two eyes of 11 naive patients with indication for treatment but not in therapy yet (Group 1) and forty-four eyes of 22 patients treated with Dupilumab for at least 4 months (subcutaneous administration of 300 mg every 2 weeks) (Group 2). Either patients treated with Dupilumab or naive patients with moderate-to-severe forms of AD had a tear film instability (TBUT and NIKBUT reduced), whereas the quantity of the tear film was overall normal (Schirmer test and TMH), without statistically significant differences between the two groups. When Meibography was performed with the Keratograph, the difference between Group 1 and Group 2 was statistically significant in terms of Meiboscore (p = 0.0043 and p = 0.0242, respectively), as well as the difference in terms of mean RS. These results paired well with the confocal microscopy results in which we found a decrease in the goblet cell population in the conjunctival epithelium in the treated group (5.2 cells/mm), along with inflammatory cells that were more concentrated around the adenoid lumina of the meibomian glands. Conclusions: In recent years, the use of Dupilumab has been increasing, but mild-to-severe conjunctivitis is a common side effect. Our major results demonstrate a loss of meibomian glands at the Keratograph examination: we can assume a reduced meibum secretion and an evaporative dry eye with MGD. We suggest that the inflammation of the ocular surface may involve not only the cornea and the conjunctiva, but also the meibomian glands, and Dupilumab may play a role. However, the frequency of clear conjunctivitis is not as common as reported in the literature.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae
    Vingopoulos, Filippos
    Lazzaro, Douglas R.
    INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, 2020, 13 : 303 - 305
  • [2] Observation of the clinical features of dupilumab-associated facial erythema
    Wu, Hao
    Zhang, Weiming
    Wu, Zhongxiao
    Shen, Yanna
    Zhang, Li
    Yang, Mouzhe
    Ren, Yougang
    Mao, Feng
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2023, 40 (06): : 741 - 746
  • [4] TREATMENT OF DUPILUMAB-ASSOCIATED KERATOCONJUNCTIVITIS
    Blanco, J.
    Knight, T.
    Bose, P.
    Boente, C.
    Vitalpur, G.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S159 - S159
  • [5] Dupilumab-Associated Sezary Syndrome
    Hamp, Austin
    Hanson, Jamie
    Alhatem, Albert
    Schwartz, Robert A.
    INDIAN JOURNAL OF DERMATOLOGY, 2023, 68 (04) : 459 - 462
  • [6] Dupilumab-associated ulcerative keratitis
    Matthew M Wilson
    Philipp K Roberts
    Mark Daniell
    International Journal of Ophthalmology, 2022, 15 (06) : 1020 - 1022
  • [7] Dupilumab-associated ulcerative keratitis
    Wilson, Matthew M.
    Roberts, Philipp K.
    Daniell, Mark
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2022, 15 (06) : 1020 - 1022
  • [8] Dupilumab-associated ocular surface disease: Clinical characteristics and treatment
    Topham, Christina
    Bohner, Austin
    Haynes, Dylan
    Brazil, Molly
    Clements, John
    Chamberlain, Winston D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB74 - AB74
  • [9] Dupilumab-associated ocular manifestations: A review of clinical presentations and management
    Wu, Duoduo
    Daniel, Benjamin S.
    Lai, Andre J. X.
    Wong, Nathan
    Lim, Dawn K. A.
    Murrell, Dedee F.
    Lim, Blanche X. H.
    Mehta, Jodhbir S.
    Lim, Chris H. L.
    SURVEY OF OPHTHALMOLOGY, 2022, 67 (05) : 1419 - 1442
  • [10] Dupilumab-Associated Eosinophilic Granulomatosis With Polyangiitis
    Persaud, Purnadeo
    Karmali, Rehan
    Sankar, Parvathy
    Majid, Muhammad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (08)